Результаты поиска

SARS-CoV-2/COVID-19 and its relationship with NOD2 and ubiquitination.

COVID-19 infection activates the immune system to cause autoimmune and autoinflammatory diseases. We provide a comprehensive review of the relationship between SARS-CoV-2, NOD2 and ubiquitination. COVID-19 infection partly results from host inborn errors and genetic factors and can lead to autoinflammatory disease. The interaction between defective NOD2 and viral infection may trigger NOD2-associated disease. SARS-CoV-2 can alter UBA1 and abnormal ubiquitination leading to VEXAS syndrome. Both NOD2 and ubiquitination play important roles in controlling inflammatory process. Receptor interactin

Совпадение в полном тексте источника
… Arthritis Rheum. 2013;43(1):125–130. doi: 10.1016/j.semarthrit.2012.12.005. 21. Yao Q., Zhou L., Cusumano P., Bose N., Piliang M., Jayakar B., et al. A new category of autoinflammatory disease associated with NOD2 gene mutations. Arthritis Res Ther. 2011;13(5):R148. doi: 10.1186/ar3462. 22. … Arthritis Rheum. 2021;73(10):1886–1895. doi: 10.1002/art.41743. 37. Diarra A., Duployez N., Fournier E., Preudhomme C., Coiteux V., Magro L., et al. Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience. …

Ход работы сессии 31st Европейский педиатрический конгресс по педиатрии: часть 2.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Ann Rheum Dis. 2015;74(8):1515-21. Aulie HA, et al. Pediatr Rheumatol Online J. 2018;16(1):85. Evensen K, et al. J Rheumatol. 2016;43(4):810-5. Tyden H, et al. RMD Open. 2017;3(2):e000508. … Ann Rheum Dis 68(8):1322–1327 Yildirim A, Önder ME, Özkan D. Ultrasonographic evaluation of distal femoral and talar cartilage thicknesses in patients with early rheumatoid arthritis and their relationship with disease activity. Clin Rheumatol 41(7):2001-2007. …

YKL-40-A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients?

YKL-40 is a 40 kDa glycoprotein produced by cancer cells, inflammatory cells and stem cells. It probably has a role in cell proliferation an … ons, cardiovascular disease, diabetes, chronic obstructive lung disease, asthma, liver fibrosis and rheumatoid arthritis. Co-morbidity should therefore always be considered in patients with cancer, since other sources than cancer cells can increase plasma YKL-40 levels. Future focused translational research projects combining basic and clinical research …

Canadian Society of Nephrology Commentary on the Evolving Kidney Disease Improving Global Outcomes Adult Glomerulonephritis Guidelines.

Purpose of reviewThe purpose of this commentary is to address the challenges of implementing the evolving Kidney Disease Improving Global Outcomes (KDIGO) glomerulonephritis (GN) guidelines within the Canadian health care context, highlighting barriers to adoption of the guidelines and discussing contextual issues unique to Canada.Sources of informationThe KDIGO 2021 guidelines with 2024 updates in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis and lupus nephritis, as well as the 2025 updated guideline for immunoglobulin A (IgA) nephropathy.MethodsA Canadian Society of Nephro

Совпадение в полном тексте источника
… Ann Rheum Dis. 2018;77(8):1143-1149. 91. Karras A, Pagnoux C, Haubitz M, et al. Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. Ann Rheum Dis. 2017;76(10):1662-1668. 92. Pope V, Sivashanmugathas V, Moodley D, Gunaratnam L, Barra L. … Semin Arthritis Rheum. 2023;60:152189. 93. Pena-Vizcarra OR, Zavala-Miranda MF, Juarez-Cuevas B, et al. Effect of antimalarials on clinical outcomes in lupus nephritis. Rheumatology (Oxford). 2024;63(8):2230-2238. 94. Petri M. …

Cellular therapies for rheumatic disease.

PURPOSE OF REVIEW: Cellular therapies, particularly chimeric antigen receptor (CAR)-modified lymphocytes, have progressed from experimental oncology into serious consideration for selected autoimmune rheumatic diseases. Autologous and emerging allogeneic CAR-T platforms now offer the possibility of deep, drug-free remission in systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), systemic sclerosis (SSc), and related conditions for which conventional therapies remain inadequate. This timely article reviews the rationale, current clinical experience, safety profile, and …

Rituximab-Associated Flare of Cryoglobulinemic Vasculitis.

BackgroundPatients with cryoglobulinemic vasculitis (CV) can develop disease flare after rituximab administration. The objective of our study was to describe the prevalence, clinical characteristics, predisposing factors, and outcomes of patients with rituximab-associated flare of CV.MethodsWe conducted a retrospective study in a tertiary referral center until March 25, 2020.ResultsAmong 64 patients with CV who received rituximab therapy in our center, 14 (22%) developed disease flare. Median age was 67.5 years. Seven patients (50%) had type II CV and the other half had either type I (n = 6) o

Совпадение в полном тексте источника
… Arthritis Rheum. 2009;60:3848–3855. doi: 10.1002/art.25000. 12. Misbah S.A. … Arthritis Rheum. 2010;62:3122–3123. doi: 10.1002/art.27666. 13. Jones J.D., Hamilton B.J., Skopelja S., Rigby W.F. Induction of interleukin-6 production by rituximab in human B cells. Arthritis Rheum. 2014;66:2938–2946. doi: 10.1002/art.38798. 14. Yang G., Gong P., Ioakimidis T., et al. …

Ассоциация увеита с педиатрическими аутоиммунными заболеваниями на основе исследования TriNetX.

Расследовать риск увеита среди таких пациентов. В ретроспективном когортном исследовании использовалась база данных TriNetX и были приняты на работу педиатрические аутоиммунные пациенты, диагностированные в период с января 1st 2004 и декабрь 31st 2022. Неавтоиммунная группа была произвольно выбрана пациентами-контролями в разбивке по полу, возрасту и индексу года. Главным результатом этого является появление новых увеитов. 175,328 Пациенты педиатрии с аутоиммунными заболеваниями (средний возраст) 10.7 +/- 5.1 годы; 55.8% - женщины; 66.2% Белый) и 175,328 Пациенты педиатрии без аутоиммунных заб

Совпадение в аннотации оригинала
To investigate for the risk of uveitis among such patients. A retrospective cohort study utilized the TriNetX database and recruited pediatr … with specific autoimmune conditions. Conditions include inflammatory arthritis, systemic autoimmune rheumatic diseases, systemic vasculitis, inflammatory bowel disease, psoriasis, multiple sclerosis, and immune thrombocytopenic purpura. Using hazard ratios HR for comparison, we were able to identify that, out of the previously broadly defined category o …

B-cells in pulmonary arterial hypertension: friend, foe or bystander?

There is an unmet need for new therapeutic strategies that target alternative pathways to improve the prognosis of patients with pulmonary arterial hypertension (PAH). As immunity has been involved in the development and progression of vascular lesions in PAH, we review the potential contribution of B-cells in its pathogenesis and evaluate the relevance of B-cell-targeted therapies. Circulating B-cell homeostasis is altered in PAH patients, with total B-cell lymphopenia, abnormal subset distribution (expansion of naïve and antibody-secreting cells, reduction of memory B-cells) and chronic acti

Совпадение в полном тексте источника
… Ann Rheum Dis 2022; 81: 1281–1289. doi: 10.1136/annrheumdis-2021-222088 111. Matsushita T. Regulatory and effector B cells: friends or foes? J Dermatol Sci 2019; 93: 2–7. doi: 10.1016/j.jdermsci.2018.11.008 112. Dumoitier N, Chaigne B, Régent A, et al. … Arthritis Rheum 2006; 54: 192–201. doi: 10.1002/art.21526 114. González-Tajuelo R, de la Fuente-Fernández M, Morales-Cano D, et al. Spontaneous pulmonary hypertension associated with systemic sclerosis in P-selectin glycoprotein ligand 1-deficient mice. …

CAR-T cell therapy for treatment-refractory rheumatic autoimmune diseases: a systematic review of clinical outcomes and safety profiles.

OBJECTIVES: Current therapeutic paradigms for treatment-refractory rheumatic diseases rely on chronic immunosuppression with variable efficacy and potential for cumulative toxicity. We systematically synthesised evidence on the clinical efficacy, safety and durability of chimeric antigen receptor T-cell (CAR-T) therapy in autoimmune rheumatic diseases. METHODS: We conducted a systematic review following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PROSPERO: CRD42025641602). Five databases were searched from inception to February 2025 for primary studies inves…

Adiponectin signalling in bone homeostasis, with age and in disease.

Adiponectin is the most abundant circulating adipokine and is primarily involved in glucose metabolism and insulin resistance. Within the bone, osteoblasts and osteoclasts express the adiponectin receptors, however, there are conflicting reports on the effects of adiponectin on bone formation and turnover. Many studies have shown a pro-osteogenic role for adiponectin in in vivo murine models and in vitro: with increased osteoblast differentiation and activity, alongside lower levels of osteoclastogenesis. However, human studies often demonstrate an inverse relationship between adiponectin conc

Совпадение в полном тексте источника
… Rheum. Dis. 1994;53:565–568. doi: 10.1136/ard.53.9.565. 78. Tang Q, et al. Association of osteoarthritis and circulating adiponectin levels: a systematic review and meta-analysis. Lipids Health Dis. 2018;17:189. doi: 10.1186/s12944-018-0838-x. 79. Doucette CR, et al. … Rheum. Dis. 2009;68:295–296. doi: 10.1136/ard.2008.095737. 87. Giambelli R, et al. Adiponectin serum levels and disease severity in the STR/Ort mouse model of osteoarthritis. Osteoarthr. Cartil. 2016;24:S85. doi: 10.1016/j.joca.2016.01.180. 88. AIHW. …

MPO-ANCA-Associated Hypertrophic Pachymeningitis Mimicking IgG4-Related Disease: A Case Report and Literature Review.

Hypertrophic pachymeningitis (HP) is a rare and chronic clinical disease characterized by thickening of the dura mater, leading to persistent headache, cranial neuropathy, seizures, and other neurological symptoms. Immune-mediated causes, particularly antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis and IgG4-related disease (IgG4-RD), are among the most common etiologies. We report a case of a 54-year-old female with recurrent headache, blepharoptosis, hearing loss, and markedly elevated inflammatory markers. Blood tests, and serum levels of IgG4 were within normal ranges. Cont

Совпадение в полном тексте источника
… Ann Rheum Dis . 2024;83(1):30–47. doi: 10.1136/ard-2022-223764 17. Jang Y, Lee S, Jung K, Chu K, Lee SK. Rituximab treatment for idiopathic hypertrophic pachymeningitis. J Clin Neurosci . 2017;13(2):155–161. 18. Guillevin L, Pagnoux C, Karras A, et al. … Ann Rheum Dis . 2023;82(7):937–944. doi: 10.1136/ard-2022-223559 20. Wallace ZS, Miloslavsky EM. Management of ANCA associated vasculitis. …

Распространение и идентификация типа 1 диабет у взрослых китайцев с недавно диагностированным диабетом.

АИМ: Цель этого исследования заключалась в оценке распространенности скрытого аутоиммунного диабета среди взрослых (ЛАДА) и классического типа 1 Диагноз сахарного диабета (T1DM) у недавно диагностировавшегося взрослого диабета в Китае. МЕТОД: Это перекрестное исследование 17,349 вновь диагностированный диабет у взрослых ≥30 лет с 46 Больницы 31 месяцев. Демографические характеристики, клинические особенности и медицинская история были собраны квалифицированными исследователями. T1DM в целом состояли из классических T1DM и ЛАДА. Классический T1DM был определен на основе клинического фенотипа ин

Совпадение в полном тексте источника
… Ann Rheum Dis . 2020 ; 79 : 837 – 39 . 32332072 10.1136/annrheumdis-2020-217566 22 Tufan A , Avanoğlu Güler A , Matucci-Cerinic M . COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. … Semin Arthritis Rheum . 2020 ; 50 : 1191 – 201 . 10.1016/j.semarthrit.2020.07.007 32931985 PMC7832282 …

The Role of Angiogenesis in Haemophilic Arthropathy: Where Do We Stand and Where Are We Going?

Haemophilia is an inherited bleeding disorder that can lead to degenerative joint arthropathy due to recurrent bleeding episodes affecting the musculoskeletal system of the patient. The cause of bleeding can be either traumatic or spontaneous. The pathogenesis of haemophilic arthropathy is unclear as many factors like iron, inflammatory cytokines, and angiogenic factors contribute to this process. Blood into joints can deteriorate the bone to such an extent that the patient experiences pain, reduction of the range of movement, and deformity of the joint, conditions that could have a great impa

Совпадение в полном тексте источника
… Internet] https://www.boundless.com/physiology/textbooks/boundless-anatomy-and-physiology-textbook/joints-8/synovial-joints-92/nerve-and-blood-supply-517-16/ 5 Morris CJ Blake DR Wainwright AC Steven MM Relationship between iron deposits and tissue damage in the synovium: an ultrastructural study Ann Rheum … infliximab therapy J Am Acad Dermatol 2006 54 1003 1012 16713454 10.1016/j.jaad.2006.01.038 39 Nakahara H Song J Sugimoto M Hagihara K Kishimoto T Yoshizaki K Nishimoto N Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis Arthritis Rheum …

Phase Ib, multicentre, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered mosunetuzumab in participants with systemic lupus erythematosus.

OBJECTIVE: To determine the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of subcutaneously administered mosunetuzumab, a CD20xCD3 T-cell-engaging bispecific antibody, in participants with systemic lupus erythematosus (SLE). METHODS: This phase Ib, multicentre, open-label, dose-escalation study enrolled 15 participants diagnosed with active autoantibody-positive SLE, demonstrated by an SLE Disease Activity Index 2000 (SLEDAI-2K) score ≥4 at screening. The study included two fixed-dosing dose-finding cohorts (1.6 mg or 5 mg of mosunetuzumab on day 1) and three step-up d

Совпадение в полном тексте источника
… 2010 62 222 33 10.1002/art.27233 20039413 PMC4548300 10 Rovin BH Furie R Latinis K et al Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study Arthritis Rheum 2012 64 1215 26 10.1002/art.34359 22231479 11 Furie RA … Aroca G Cascino MD et al B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial Ann Rheum Dis 2022 81 100 7 10.1136/annrheumdis-2021-220920 34615636 PMC8762029 12 Furie RA Rovin BH Garg JP et al Efficacy and Safety …

Passive Monoclonal and Polyclonal Antibody Therapies

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Selectively inhibits T-cell activation through costimulation blockade binds to both CD80 and CD86 blocking CD28 Belimumab Benlysta FDA 2011 EU 2011 LymphoStat-B Human monoclonal antibody IgG1λ Disease modifying Kidney transplant phase II Treat SLE (testing phase III for renal involvement) Phase II Rheum … Efungumab MYC123 Mycograb Mycograb C28Y Human scFv Antiinfectious agent Invasive Candida infection Intravenous Heat shock protein 90 (Hsp90) Eldelumab Mdx 1100 Human monoclonal antibody IgG1κ Crohn's disease phase IIa no significant response, ulcerative colitis phase IIb prim endpoint not achieved Rheum …

Understanding Autoimmunity: Mechanisms, Predisposing Factors, and Cytokine Therapies.

Autoimmunity refers to an organism's immune response against its own healthy cells, tissues, or components, potentially leading to irreversible damage to vital organs. Central and peripheral tolerance mechanisms play crucial roles in preventing autoimmunity by eliminating self-reactive T and B cells. The disruption of immunological tolerance, characterized by the failure of these mechanisms, results in the aberrant activation of autoreactive lymphocytes that target self-tissues, culminating in the pathogenesis of autoimmune disorders. Genetic predispositions, environmental exposures, and immun

Drug-Induced Pulmonary Toxicity in the Era of Immunotherapy and Biologics: A Narrative Review of Mechanism, Diagnosis, and Management.

Drug-induced interstitial lung disease (DI-ILD) has emerged as a clinically significant complication associated with a broadening spectrum of therapeutic agents. DI-ILD can result in significant morbidity and mortality if not promptly diagnosed and treated. In this review, we synthesize current evidence concerning the epidemiology, risk factors, pathophysiological mechanisms, clinical manifestations, diagnostic approaches, and management strategies of DI-ILD, with focused emphasis on three major therapeutic groups: immune checkpoint inhibitors (ICIs), chimeric antigen receptor T-cell (CAR-T) t

Совпадение в полном тексте источника
… Semin Arthritis Rheum. 2010;40(2):147–63. 10.1016/j.semarthrit.2009.09.001. 19914686 10.1016/j.semarthrit.2009.09.001 55. … Roubille C Haraoui B Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review Semin Arthritis Rheum 2014 43 5 613 626 10.1016/j.semarthrit.2013.09.005 24231065 Roubille C, Haraoui B. …

Cellular Therapy for Systemic Autoimmune Diseases: New Opportunities for Future Research and Interdisciplinary Collaboration.

Systemic autoimmune diseases (sAIDs) affect 1 in 10 people and represent a leading cause of death in women under the age of 65 years. Despit … trategies to bridge the gap between preclinical and clinical research, foster collaboration between rheumatologists and hematologists-oncologists, and develop optimal treatment protocols grounded in solid science. This manuscript summarizes the main concepts put forward and makes practical recommendations for advancing the development of cellular therap …

A systematic review and meta-analysis of the efficacy and safety of iguratimod in the treatment of inflammatory arthritis and degenerative arthritis.

OBJECTIVE: To assess the efficacy and safety of iguratimod (IGU) in the treatment of inflammatory arthritis and degenerative arthritis. MET … flammatory arthritis were included, including ankylosing spondylitis (AS), osteoarthritis (OA), and rheumatoid arthritis (RA). For AS, the meta-analysis results showed that IGU may decrease BASDAI (SMD -1.68 [-2.32, -1.03], P < 0.00001) and BASFI (WMD -1.29 [-1.47, -1.11], P < 0.00001); IGU may also decrease inflammatory factor [ESR: (WMD -10.33 [-14.96 …

Development of clinical utility of zoledronic acid and patient considerations in the treatment of osteoporosis.

Osteoporosis is a major health concern, which results in the increased risk of fractures. There is a high risk for the first or consecutive fractures leading to considerable morbidity and debilitating consequences if osteoporosis is untreated. Currently, bisphosphonates are the mainstay of treatment for osteoporosis though long-term persistence and adherence to bisphosphonates, especially those taken orally, remain low. This medication noncompliance has serious consequences on osteoporotic patients as it is associated with a significantly higher fracture risk. Intravenous (IV) zoledronic acid

Совпадение в полном тексте источника
… Arthritis Rheum. 2001;44(7):1496–1503. doi: 10.1002/1529-0131(200107)44:7<1496::AID-ART271>3.0.CO;2-5. 59. Reid DM, Devogelaer JP, Saag K, et al. … Arthritis Rheum. 2006;54(6):1838–1846. doi: 10.1002/art.21918. 91. Sunyecz J. Optimizing dosing frequencies for bisphosphonates in the management of postmenopausal osteoporosis: patient considerations. Clin Interv Aging. 2008;3(4):611–627. doi: 10.2147/cia.s2496. 92. …